Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Asset Writedowns and Impairment (2016 - 2024)

Icu Medical (ICUI) has disclosed Asset Writedowns and Impairment for 15 consecutive years, with $4.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Asset Writedowns and Impairment rose 16466.67% year-over-year to $4.4 million, compared with a TTM value of $5.3 million through Mar 2025, up 628.29%, and an annual FY2024 reading of $5.8 million, up 592.12% over the prior year.
  • Asset Writedowns and Impairment was $4.4 million for Q4 2024 at Icu Medical, up from $11000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.4 million in Q4 2024 and bottomed at -$548000.0 in Q1 2022.
  • Average Asset Writedowns and Impairment over 5 years is $842000.0, with a median of $395500.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment skyrocketed 27300.0% in 2022, then crashed 159.47% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $4.4 million in 2020, then plummeted by 99.93% to $3000.0 in 2021, then surged by 27300.0% to $822000.0 in 2022, then plummeted by 103.28% to -$27000.0 in 2023, then surged by 16466.67% to $4.4 million in 2024.
  • Business Quant data shows Asset Writedowns and Impairment for ICUI at $4.4 million in Q4 2024, $11000.0 in Q3 2024, and $821000.0 in Q2 2024.